ClinicalTrials.gg
CompletedNCT04795427Updated Apr 18, 2025

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

A Phase 2 interventional study of asciminib and best available treatment in Leukemia, Chronic Myelogenous, sponsored by Novartis Pharmaceuticals. Completed at 20 sites in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-04-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 8 open to participants now, 13 under way, 2 of them phase 3. asciminib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
13th of 21
84 · median 100
Started
2021
with 4 others
Phase 2
11 of 21
6 open now
Registered
7th of 21
by date
Lead sponsor
12 of 21
Novartis Pharmaceuticals

Among the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 13th largest by enrollment, is one of 5 that started in 2021, is one of 11 in phase 2, and was the 7th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

8 of the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About asciminib

asciminib: first FDA approval 2021 (SCEMBLIX), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The purpose of this Chinese bridging study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of asciminib versus best available therapy in Chinese patients with Chronic Myelogenous Leukemia in chronic phase, previously treated with 2 or more tyrosine kinase inhibitors to support related indication registration in China.

The primary objective of the study is to evaluate the Major Molecular Response (MMR) rate of asciminib treatment at 24 weeks.

Read the detailed description

The purpose of this Chinese bridging study is to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of asciminib versus best available therapy (BAT) in Chinese patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs) to support related indication registration in China.

This study will enroll the participants 1) who failed their most recent TKI therapy by meeting the definition of treatment failure as per the 2013 European Leukemia Net (ELN) guidelines, or 2) who were intolerant to the most recent TKI therapy and must have BCR-ABL1 ratio > 0.1% IS at screening.

Eligible participants will be randomized into asciminib arm or the BAT arm on a 2:1 ratio, to receive asciminib treatment (continuous 40 mg BID) or BAT from Day 1 until the end of study treatment period defined as 96 weeks after the last participant receives the first dose.

03

Conditions studied

  • Leukemia, Chronic Myelogenous

Keywords

  • Chronic Myelogenous Leukemia in chronic phase
  • Chronic Myelogenous Leukemia
  • CML-CP
  • Chronic
  • Chronic Phase
  • ABL001
  • asciminib
  • prior treatment with 2 or more tyrosine kinase inhibitors (TKIs)
  • major molecular response
  • MMR
  • Chinese patients
  • phase ll
  • open label
  • best available therapy
  • BAT
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diagnosed as CML-CP:

  1. Participants must meet all of the following laboratory values at the screening visit:

    \< 15% blasts in peripheral blood and bone marrow \< 30% blasts plus promyelocytes in peripheral blood and bone marrow \< 20% basophils in the peripheral blood

    • 50 x 10\^9/ L (≥ 50,000/mm3) Transient prior therapy related thrombocytopenia (\< 50,000/mm3 for ≤ 30 days prior to screening) is acceptable No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly
  2. Prior treatment with a minimum of 2 prior ATP-competitive TKIs.
  3. Failure (adapted from the 2013 European Leukemia Net (ELN) Guidelines) or intolerance to the most recent TKI therapy at the time of screening.
  4. Evidence of typical BCR-ABL1 transcript [e14a2 and/or e13a2] at the time of screening which are amenable to standardized RQ-PCR quantification

Exclusion criteria

Exclusion Criteria:

  1. Known presence of the T315I mutation at any time prior to study entry
  2. Known second chronic phase of CML after previous progression to AP/BC
  3. Previous treatment with a hematopoietic stem cell transplantation
  4. Participants planning to undergo hematopoietic stem cell transplantation
  5. Cardiac or cardiac repolarization abnormality, including any of the following:

    History within 6 months prior to starting study treatment of myocardial infarction, angina pectoris, coronary artery bypass graft cardiac arrhythmias , complete left bundle branch block, high-grade AV block at screening ≥450 msec (male participants), ≥460 msec (female participants)

    Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:

    Risk factors for Torsades de Pointes including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia Concomitant medication(s) with a "Known risk of Torsades de Pointes" that cannot be discontinued or replaced 7 days prior to starting study drug by safe alternative medication.

    Inability to determine the QTcF interval

  6. History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    asciminb arm

    Patients will receive asciminib (40 mg BID continuous)

    Drug: asciminib

  • Experimental
    best available treatment arm

    Patients will receive best available therapy chosen by investigator

    Other: best available treatment

Interventions

  • Asciminib comes in 20 mg and 40 mg tablets and is taken orally twice daily

    Also known as: ABL001

  • Otherbest available treatment

    Best available treatment will be based on investigator's choice identified prior to randomization. Dose and frequency will depend on label and institutional guidelines for various BAT

06

What researchers measure

Primary outcomes

  1. Major molecular response rate of asciminib

    Evaluate the major molecular response rate at 24 weeks in asciminib arm

    Time frame: week 24

Secondary outcomes

  1. Cytogenetic response (CyR) rate

    Evaluate the cytogenetic response rate (Complete, Partial, Major, Minor, Minimal, no response) at and by all scheduled data collection time points including 24, 48 and 96 weeks for both asciminib arm and best available treatment arm.

    Time frame: 24, 48, 96 weeks

  2. Major molecular response rate of best available treatment arm

    Evaluate the major molecular response rate at week 24 of best available treatment arm, and compare with asciminib arm

    Time frame: week 24

  3. Major molecular response rate of both asciminib arm and BAT armn time points

    Evaluate the major molecular response rate, collected at all scheduled data collection time point (except week 24)

    Time frame: Up to all participants received at least 96 weeks of randomized study treatment, except week 24

  4. major molecular response rate by all scheduled data collection time points

    Evaluate the major molecular rate by all scheduled data collection time points including 24, 48 and 96 weeks by treatment group

    Time frame: Up to all participants received at least 96 weeks of randomized study treatment

  5. Time to major molecular response rate

    Evaluate the time from the date of the first dose of study drug to the date of the first documented MMR by treatment group

    Time frame: Up to all participants received at least 96 weeks of randomized study treatment

  6. Duration of major molecular response

    First document major molecular response to loss of MMR up to 96 weeks after last participant receive the first dose

    Time frame: Up to all participants received at least 96 weeks of randomized study treatment

  7. Overall survival

    To evaluate the time from the date of randomization to the date of death (including the survival follow-up period)

    Time frame: Up to all participants received at least 96 weeks of randomized study treatment, plus 30 days for safety follow up

  8. Progression free survival

    Evaluate the time from the date of randomization to the earliest occurrence of documented disease progression to AP/BC or the date of death from any cause (including progressions and deaths observed during the survival follow-up period)

    Time frame: Up to all participants received at least 96 weeks of randomized study treatment, plus 30 days for safety follow up

  9. Pharmacokinetics (PK) parameter of asciminib: Cmax

    Characterize PK of asciminib in the Chinese CML-CP population. Cmax is the maximum (peak) observed plasma drug concentration after dose administration (ng/mL).

    Time frame: Week 2 Day 1 (W2D1)

  10. PK parameter of asciminib: Tmax

    Characterize PK of asciminib in the Chinese CML-CP population. Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration (hr).

    Time frame: Week 2 Day 1 (W2D1)

  11. PK parameter of asciminib: Ctrough

    Characterize PK of asciminib in the Chinese CML-CP population. Trough plasma concentrations (Ctrough)

    Time frame: Week 2 Day 1 (W2D1)

  12. PK parameter of asciminib: AUCtau

    Characterize PK of asciminib in the Chinese CML-CP population. The partial area under the plasma concentration-time curve from dose time to tau (ng\*hr/mL). For a bid regimen, Tau=12h.

    Time frame: Week 2 Day 1 (W2D1)

  13. PK parameter of asciminib: AUClast

    Characterize PK of asciminib in the Chinese CML-CP population. AUClast is the The AUC from the time of dosing to the time of the last measurable plasma concentration (Tlast) (ng\*hr/mL)

    Time frame: Week 2 Day 1 (W2D1)

07

Study locations

20 sites
  • Novartis Investigative Site
    Chongqing, Chongqing 400010, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510515, China
  • Novartis Investigative Site
    Shenzhen, Guangdong 518037, China
  • Novartis Investigative Site
    Zhengzhou, Henan 450008, China
  • Novartis Investigative Site
    Zhengzhou, Henan 450052, China
  • Novartis Investigative Site
    Wuhan, Hubei 430022, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210000, China
  • Novartis Investigative Site
    Nantong, Jiangsu 226000, China
  • Novartis Investigative Site
    Suzhou, Jiangsu 215004, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
  • Novartis Investigative Site
    Chang Chun, Jilin 130021, China
  • Novartis Investigative Site
    Xian, Shanxi 710004, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310003, China
  • Novartis Investigative Site
    Wenzhou, Zhejiang 325000, China
  • Novartis Investigative Site
    Beijing, 100044, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Shanghai, 200025, China
  • Novartis Investigative Site
    Shenyang, 110004, China
  • Novartis Investigative Site
    Tianjin, 300020, China
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in May 2023, 17 months.

Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's 17 months is below that.

Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2021
First posted
Mar 12, 2021
StartActual
Dec 6, 2021
Primary completionActual
May 29, 2023
CompletionActual
Nov 18, 2024
Last update
Apr 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04795427
Responsible party
Sponsor
First posted
Mar 12, 2021
Start date
Dec 6, 2021
Primary completion
May 29, 2023
Completion
Nov 18, 2024
Last update
Apr 18, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asciminib

Start the discussion